Bellicum Pharma (BLCM) Selected for Inclusion in NASDAQ Biotechnology Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Bellicum to be Added to the NASDAQ Biotechnology Index
December 14, 2015 4:09 PM ESTHOUSTON--(BUSINESS WIRE)-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company has been selected for inclusion in the NASDAQ Biotechnology Index® (Nasdaq: NBI). This addition will be effective prior to market open on Monday, December 21, 2015.
... More